Back to search results

Kisspeptin for Reproductive Disorders and Long COVID

This study is looking at how a substance called kisspeptin 112-121 affects the body, specifically how it influences the reproductive system. Researchers want to compare the response to kisspeptin in people with and without conditions like reproductive disorders, neurodegeneration, SARS-CoV-2 (the virus that causes COVID-19), and Long COVID. You might be able to join if you are a woman aged 18-45 or a man aged 18-60, and you're not currently taking medications that affect your reproductive hormones. The main goal is to see if there's a difference in how much luteinizing hormone (LH), a reproductive hormone, changes after receiving kisspeptin in people with these conditions compared to healthy individuals. The study is currently unclear on its recruitment status and plans to enroll 40 participants.

Study design
This is an interventional study comparing responses to kisspeptin in different groups. It plans to enroll 40 participants.
What's involved
You would receive a single injection of kisspeptin and have blood drawn before and after the injection (two times total) during a one to two-hour study visit.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at the day of the study visit (one to two hours).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07224490

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Recruiting
PHASE1Ages 18–60Interventional
Stephanie B. Seminara, MD
~40 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Kisspeptin 112-121

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Difference in mean luteinizing hormone (LH) amplitude between cases and controls
Measured over Day of study visit (one to two hours)

Conditions

Reproductive Disorder
Neurodegeneration
SARS-CoV 2
Long COVID

Explore related trials

Post-Acute Sequelae of COVID-19Severe Acute Respiratory Syndrome

NCT07224490

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Massachusetts General Hospital

    Boston, Massachusettsstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Study Coordinator
[email protected]
617-643-2308
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Female (ages 18-45 years) or Male (ages 18-60 years)
No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration
For women, negative serum hCG pregnancy test
For cases, diagnosis of post-covid-19 syndrome
For controls, history of prior covid infection but no diagnosis of post-covid-19 syndrome

Exclusion

Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol or the interpretation of results
Active use of illicit drugs (not including marijuana)
For women,
Pregnant
Trying to become pregnant during protocol participation
Breast feeding
Surgical or natural menopause

What this trial measures

  • Difference in mean luteinizing hormone (LH) amplitude between cases and controlsDay of study visit (one to two hours)

    Difference between cases and controls of mean LH amplitude in response to kisspeptin